Carter Cliff

Carter Cliff is a prominent figure in the biotechnology sector, currently serving as the CEO of Papillon Therapeutics Inc, where the focus is on genetic medicines for inherited diseases, achieving positive Phase 1/2 results for Cystinosis. As President of StemCardia, Carter is involved in regenerative heart therapies and has secured over 60 patents from the University of Washington. As a co-founder of multiple companies, including Kenai Therapeutics and Opsis Therapeutics, Carter has contributed significantly to advancements in cellular and genetic medicines for neurodegenerative diseases and retinal regeneration, respectively, raising substantial capital and entering strategic alliances. Additionally, Carter holds a venture partnership at Saisei Ventures, which emphasizes global healthcare impacts through innovative companies. Carter's educational background includes dual Bachelor's degrees in Chemistry and Biology from the New Mexico Institute of Mining and Technology, with further studies at The University of Texas at Austin and UT Southwestern Medical Center.